A case of the 'dapsone syndrome'.
The 'dapsone syndrome' developed in a 44-year-old woman who was treated for pyoderma gangrenosum with 100 mg/day dapsone for about 5 weeks. Symptoms included fever, malaise, jaundice with hepatic dysfunction, lymphadenopathy, mononucleosis and dermatitis. These symptoms disappeared with 30 mg/day of oral prednisolone. A lymphocyte stimulation test with dapsone was positive, as was the delayed-type intradermal skin test with 0.5 and 0.05% dapsone in saline. Immunohistochemical studies of the rash and skin test reaction revealed that the dominant infiltrating T cells in the upper dermis were of the Leu 2a+ cytotoxic/suppressor-type rather than the Leu 3a+ helper/delayed hypersensitivity-type.
Saito
S
S
Department of Dermatology, Yokohama City University School of Medicine, Japan.
Ikezawa
Z
Z
Miyamoto
H
H
Kim
S
S
D000328:Adult; D003622:Dapsone / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D017511:Pyoderma Gangrenosum / Q000188:drug therapy; D012867:Skin / Q000473:pathology
D003622:Dapsone